MetaVia Inc. appointed Sarah Browne, M.D., as Chief Medical Officer effective October 12, 2026. Dr. Browne brings over 20 years of experience in clinical development and regulatory science, with specific expertise in liver and metabolic diseases including MASH. She previously served at Altimmune, Inc., where she led the development of pemvidutide through Phase 2. MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases.
